Braxia said it hopes to develop a “new generation” of independent physicians, psychologists and psychotherapists that are interested in using psilocybin to treat depression.
As part of the program, therapists will participate in delivering psychotherapy in upcoming clinical trials at Braxia that are evaluating the safety and efficacy of psilocybin in depression. Therapists would also be trained to implement psychedelics in clinical practice, pending regulatory approval.
READ: Braxia Scientific receives Canadian government funding for first-of-its-kind study on ketamine treatment for bipolar depression
"We are encouraged to see the growing number of clinical studies focused on demonstrating that psilocybin, and other potential psychedelics, may be safe and effective in treating people with multiple mental health conditions including treatment-resistant depression," Roger McIntyre, Braxia’s CEO said in a statement.
"Although psilocybin is available mostly to participants in clinical research trials, we are focused on providing healthcare professionals with the training, competencies and practical experience to address the need for safe, legal and affordable access to high-quality psilocybin-assisted therapy as these innovative treatments prepare for regulatory approval. As mental health professionals, we continually strive to deliver innovative treatment options that will result in better outcomes in persons affected by depression and related disorders for the short and long term."
Toronto-based Braxia Scientific is a medical research company with clinics that provide innovative ketamine treatments for persons with depression and related disorders. The firm currently operates multi-disciplinary community-based clinics offering rapid-onset treatments for depression located in Mississauga, Toronto, Ottawa, and Montreal.
Contact Angela at email@example.com
Follow her on Twitter @AHarmantas